INS and metabolic syndrome: Similar results were observed when also BMI, HbA1C, insulin treatment as well as anti-hypertension and anti-dyslipidemia therapies and hsCRP were considered (HR, 95% CI = 1.44, 1.10–1.90, Table 5), with HbA1C being among those added into the model, the only other risk factor remaining significantly associated with MACE (Table 5).